HTLV-I Infections Clinical Trial
Official title:
HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens
This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
The HTLV Blot 2.4 Post-Market Clinical Study is an open-label, multi-center, single-blind clinical study of neurological disorders (n=100) and HTLV known-positive (KP) specimens (n=50). This study is being conducted to support additional labeling claims and to further assess the sensitivity and specificity of the HTLV Blot 2.4 in specimens with neurological disorders and HTLV known positive specimens. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Unknown status |
NCT01467024 -
Evaluation of the MP Diagnostics HTLV Blot 2.4
|
N/A | |
| Completed |
NCT01754311 -
Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1
|
||
| Completed |
NCT03146013 -
Dual Algorithm Post Market Clinical Study
|
N/A | |
| Completed |
NCT02655471 -
Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection
|
Early Phase 1 | |
| Completed |
NCT03829709 -
Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1
|
N/A |